Routine severance amendment with no trading signal. Monitor the Q3 2026 10-Q for full agreement exhibits if detail on base salary and bonus targets is needed. No immediate catalyst for KURA shares.
KURA drugs
KURA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 30 $9.31entry
- T+1 · 4mo ago −3.22%α −3.93% · $9.01
- T+5 · 3mo ago −0.32%α −3.94% · $9.28
- T+20 · 3mo ago +41.57%α +37.60% · $13.18
- T+60 · 25d ago +3.22%α +0.76% · $9.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology entered amended executive employment agreements with its CEO, CCO, and COO modifying severance provisions. The changes enhance change-of-control severance benefits (e.g., 24-month salary for CEO in change-of-control termination, full equity acceleration). No departures, appointments, or material financial figures were disclosed.
Key Facts
- CEO Troy E. Wilson's new agreement provides 12 months base salary severance (non-change-of-control) or 24 months + 200% target bonus (change-of-control).
- CCO Brian Powl and COO Kathleen Ford each receive 12 months base salary severance (non-change-of-control) or 18 months + 150% target bonus (change-of-control).
- Change-of-control severance includes full equity acceleration (performance-based awards vest at target) for all three executives.
- Full copies of the agreements will be filed with the Q3 2026 10-Q.
Financial Impact
No dollar amounts disclosed; impact is contingent on undefined severance scenarios (base salary and target bonus values not provided).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-324202 |
| Document: 0001193125-26-324202-index-headers.html | 0001193125-26-324202 |
| Document: 0001193125-26-324202-index.html | 0001193125-26-324202 |
| Document: 0001193125-26-324202.txt | 0001193125-26-324202 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers